Company intelligence / Profile preview
MonTa Biosciences
Kgs. Lyngby / Lyngby, Capital Region of Denmark, Denmarkmontabiosciences.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
MonTa Biosciences’ lead candidate, MBS8, a lipid nanoparticle formulation containing a novel small molecule TLR7 agonist, has completed patient cohorts in an ongoing phase I clinical trial for solid tumors. The therapy has demonstrated superior anti-tumor activity in preclinical models and shows synergy with immune checkpoint inhibitors, radiotherapy, and chemotherapy. Over 45 patients have been treated as of mid-2024 at sites in Denmark, Belgium, and Spain[2][3].
- Therapeutic areas
- Oncology
- Modalities
- Lipid nanoparticle delivery therapySmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed.
Beyond the preview
Go deeper on MonTa Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MonTa Biosciences.